Clinical Trial Update: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating two sequencing strategies for BRAFV600-mutant stage III–IV melanoma: dabrafenib plus trametinib followed by ipilimumab plus ni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• MEKINIST (trametinib)
• OPDIVO (nivolumab)
• TAFINLAR (DABRAFENIB)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-18